IL215325A - Chunks of proteasome inhibitors that have been lyophilized - Google Patents
Chunks of proteasome inhibitors that have been lyophilizedInfo
- Publication number
- IL215325A IL215325A IL215325A IL21532511A IL215325A IL 215325 A IL215325 A IL 215325A IL 215325 A IL215325 A IL 215325A IL 21532511 A IL21532511 A IL 21532511A IL 215325 A IL215325 A IL 215325A
- Authority
- IL
- Israel
- Prior art keywords
- proteasome inhibitors
- lyophilized cakes
- cakes
- lyophilized
- proteasome
- Prior art date
Links
- 229940079156 Proteasome inhibitor Drugs 0.000 title 1
- 239000003207 proteasome inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16652909P | 2009-04-03 | 2009-04-03 | |
| EP09305291A EP2238973A1 (en) | 2009-04-07 | 2009-04-07 | Lyophilized preparations of proteasome inhibitors |
| US28895509P | 2009-12-22 | 2009-12-22 | |
| PCT/US2010/029597 WO2010114982A2 (en) | 2009-04-03 | 2010-04-01 | Lyophilization cakes of proteasome inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL215325A0 IL215325A0 (en) | 2011-12-29 |
| IL215325A true IL215325A (en) | 2016-06-30 |
Family
ID=41130433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215325A IL215325A (en) | 2009-04-03 | 2011-09-22 | Chunks of proteasome inhibitors that have been lyophilized |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8785418B2 (pt) |
| EP (2) | EP2238973A1 (pt) |
| JP (1) | JP5722871B2 (pt) |
| KR (1) | KR20120016082A (pt) |
| CN (1) | CN102387790B (pt) |
| AR (1) | AR084663A1 (pt) |
| AU (1) | AU2010232632C1 (pt) |
| BR (1) | BRPI1006633A2 (pt) |
| CA (1) | CA2757463A1 (pt) |
| CL (1) | CL2011002460A1 (pt) |
| IL (1) | IL215325A (pt) |
| MX (1) | MX2011010422A (pt) |
| NZ (1) | NZ596056A (pt) |
| TW (1) | TWI484981B (pt) |
| WO (1) | WO2010114982A2 (pt) |
| ZA (1) | ZA201107852B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011087822A1 (en) * | 2009-12-22 | 2011-07-21 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
| EP2547333B1 (en) * | 2010-03-18 | 2017-08-23 | Innopharma, Inc. | Stable bortezomib formulations |
| US8263578B2 (en) * | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
| AU2011312264B2 (en) | 2010-10-05 | 2015-07-02 | Fresenius Kabi Usa, Llc | Bortezomib formulations stabilised with boric acid |
| TW201309303A (zh) * | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
| CN102784114B (zh) * | 2011-05-14 | 2016-03-02 | 山东新时代药业有限公司 | 一种硼替佐米冻干粉针及其制备方法 |
| MX2013015308A (es) * | 2011-06-22 | 2014-05-20 | Cephalon Inc | Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso. |
| CA2784240C (en) * | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
| EA021179B1 (ru) * | 2012-06-15 | 2015-04-30 | Ощество С Ограниченной Ответственностью "Тева" | Лиофилизат соединения бороновой кислоты |
| WO2014072985A1 (en) * | 2012-11-06 | 2014-05-15 | Natco Pharma Limited | Novel boronic acid derivatives as anti cancer agents |
| CN103897026A (zh) * | 2012-12-29 | 2014-07-02 | 朱继东 | 硼替佐米关键中间体的晶型，制备方法及其运用 |
| CN103897027A (zh) * | 2012-12-29 | 2014-07-02 | 曹亚英 | 关键中间体晶型，制备方法及其在硼替佐米合成中的运用 |
| WO2014102755A1 (en) * | 2012-12-31 | 2014-07-03 | Shilpa Medicare Limited | Bortezomib formulations |
| CN103070835B (zh) * | 2013-01-31 | 2015-01-07 | 江苏奥赛康药业股份有限公司 | 一种含硼替佐米的冻干组合物及其制备方法 |
| WO2014161072A1 (en) * | 2013-04-02 | 2014-10-09 | The Governing Council Of The University Of Toronto | Α-boryl isocyanides, boropeptides and boron heterocycles |
| CN103212055B (zh) * | 2013-04-19 | 2014-11-05 | 海南锦瑞制药股份有限公司 | 一种硼替佐米的药物组合物及其制备方法 |
| CN105452791B (zh) * | 2013-05-29 | 2017-05-31 | 基伊埃工程技术股份有限公司 | 提供内联灭菌冷冻干燥容纳在手推车托盘中产品的方法、用于执行该方法的系统和对该方法的使用 |
| CN103720666B (zh) * | 2013-12-16 | 2015-11-25 | 亿腾药业（泰州）有限公司 | 一种注射用硼替佐米冻干制剂的制备方法 |
| WO2016205790A2 (en) | 2015-06-19 | 2016-12-22 | Hanlin Scientific, Inc. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
| CN108135916B (zh) * | 2015-06-19 | 2022-01-28 | 北京科辉智药生物科技有限责任公司 | 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用 |
| WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
| CN106176637A (zh) * | 2016-08-24 | 2016-12-07 | 江苏豪森药业集团有限公司 | 硼替佐米的冻干制剂及其制备方法 |
| KR102579836B1 (ko) * | 2016-12-22 | 2023-09-15 | 제넨테크, 인크. | 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제 |
| RU2659160C1 (ru) * | 2017-07-10 | 2018-06-28 | Акционерное Общество "Фарм-Синтез" | Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом |
| CN110540547A (zh) * | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
| EP3824880A1 (en) * | 2019-11-25 | 2021-05-26 | Clevexel Pharma | Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5835968B2 (ja) | 1974-02-25 | 1983-08-05 | 帝人株式会社 | サイクロデキストリン包接化合物の製造法 |
| GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| JPS5920230A (ja) | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | ピルプロフエン含有薬剤 |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| FR2593809B1 (fr) | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| JPS62281855A (ja) | 1986-05-29 | 1987-12-07 | Daikin Ind Ltd | ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物 |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| GB8813682D0 (en) | 1988-06-09 | 1988-07-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
| JPH035438A (ja) | 1989-05-31 | 1991-01-11 | Kaken Pharmaceut Co Ltd | フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤 |
| CA2013485C (en) | 1990-03-06 | 1997-04-22 | John Michael Gardlik | Solid consumer product compositions containing small particle cyclodextrin complexes |
| FR2663225B1 (fr) | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| US5024997A (en) | 1990-06-22 | 1991-06-18 | American Home Products Corporation | Palatable ibuprofen solutions |
| JP3176716B2 (ja) * | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | 溶解性が向上した難水溶性薬物組成物 |
| FR2684875B1 (fr) | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| FR2702968B1 (fr) | 1993-03-23 | 1995-06-23 | Lafon Labor | Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation . |
| US5843347A (en) | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
| US5866162A (en) | 1993-08-10 | 1999-02-02 | Smithkline Beecham P.L.C. | Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6077871A (en) | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| US6346548B1 (en) | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| PT3078667T (pt) * | 2001-01-25 | 2018-12-28 | The United States Of America Represented By The Sec Dep Of Health And Human Services | Formulação de compostos de ácido borónico |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| RS53259B (sr) | 2004-03-30 | 2014-08-29 | Millennium Pharmaceuticals Inc. | Sinteza bortezomiba |
| CN101180071A (zh) * | 2004-12-07 | 2008-05-14 | 普罗特奥里克斯公司 | 抑制蛋白酶体的组合物 |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| ATE475408T1 (de) * | 2005-10-14 | 2010-08-15 | Janssen Pharmaceutica Nv | Formulierungen von tipifarnib zur intravenösen verabreichung |
| AU2007321977A1 (en) * | 2006-11-21 | 2008-05-29 | Novartis Ag | Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
-
2009
- 2009-04-07 EP EP09305291A patent/EP2238973A1/en not_active Withdrawn
-
2010
- 2010-04-01 MX MX2011010422A patent/MX2011010422A/es active IP Right Grant
- 2010-04-01 CA CA2757463A patent/CA2757463A1/en not_active Abandoned
- 2010-04-01 JP JP2012503695A patent/JP5722871B2/ja not_active Expired - Fee Related
- 2010-04-01 NZ NZ596056A patent/NZ596056A/xx not_active IP Right Cessation
- 2010-04-01 KR KR1020117026086A patent/KR20120016082A/ko not_active Abandoned
- 2010-04-01 BR BRPI1006633A patent/BRPI1006633A2/pt not_active IP Right Cessation
- 2010-04-01 EP EP10712647A patent/EP2413916A2/en not_active Withdrawn
- 2010-04-01 AU AU2010232632A patent/AU2010232632C1/en not_active Ceased
- 2010-04-01 WO PCT/US2010/029597 patent/WO2010114982A2/en not_active Ceased
- 2010-04-01 CN CN201080015692.7A patent/CN102387790B/zh not_active Expired - Fee Related
- 2010-04-02 TW TW099110311A patent/TWI484981B/zh not_active IP Right Cessation
- 2010-04-05 AR ARP100101126A patent/AR084663A1/es unknown
-
2011
- 2011-09-22 IL IL215325A patent/IL215325A/en not_active IP Right Cessation
- 2011-09-29 US US13/248,398 patent/US8785418B2/en not_active Expired - Fee Related
- 2011-10-03 CL CL2011002460A patent/CL2011002460A1/es unknown
- 2011-10-26 ZA ZA2011/07852A patent/ZA201107852B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102387790A (zh) | 2012-03-21 |
| IL215325A0 (en) | 2011-12-29 |
| CL2011002460A1 (es) | 2012-09-14 |
| AU2010232632B2 (en) | 2016-04-21 |
| CA2757463A1 (en) | 2010-10-07 |
| TW201039865A (en) | 2010-11-16 |
| EP2413916A2 (en) | 2012-02-08 |
| AU2010232632A1 (en) | 2011-11-24 |
| MX2011010422A (es) | 2011-10-17 |
| BRPI1006633A2 (pt) | 2019-09-24 |
| KR20120016082A (ko) | 2012-02-22 |
| WO2010114982A2 (en) | 2010-10-07 |
| ZA201107852B (en) | 2012-07-25 |
| TWI484981B (zh) | 2015-05-21 |
| CN102387790B (zh) | 2014-12-10 |
| AR084663A1 (es) | 2013-06-05 |
| JP5722871B2 (ja) | 2015-05-27 |
| WO2010114982A3 (en) | 2011-09-01 |
| AU2010232632C1 (en) | 2016-09-22 |
| NZ596056A (en) | 2012-10-26 |
| JP2012522795A (ja) | 2012-09-27 |
| US8785418B2 (en) | 2014-07-22 |
| EP2238973A1 (en) | 2010-10-13 |
| US20120035133A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215325A0 (en) | Lyophilization cakes of proteasome inhibitors | |
| GB201004179D0 (en) | Enzyme inhibitors | |
| GB201004178D0 (en) | Enzyme inhibitors | |
| ZA201202816B (en) | Detection of objects | |
| IL218018A0 (en) | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions | |
| ZA201202631B (en) | Hcv protease inhibitors | |
| PT2406240E (pt) | Inibidores de beta-secretase | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| GB201007384D0 (en) | Enzymes | |
| ZA201303360B (en) | Kat ii inhibitors | |
| ZA201107636B (en) | Protease inhibitors | |
| PL2417107T3 (pl) | Krystaliczne postacie saksagliptyny | |
| SG11201400102WA (en) | Inhibitors of nedd8-activating enzyme | |
| EP2635287A4 (en) | NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION | |
| ZA201303412B (en) | Kat ii inhibitors | |
| AP2013006720A0 (en) | Waste combustion chamber | |
| EP2548554A4 (en) | IN VIVO proteolysis INHIBITORS | |
| HK1165714A (en) | Lyophilization cakes of proteasome inhibitors | |
| IL216594A0 (en) | Proteasome inhibitors and uses thereof | |
| GB0920625D0 (en) | Ace of plugs | |
| GB0915927D0 (en) | Novel inhibitors | |
| GB0901616D0 (en) | Enzyme inhibitors | |
| GB0908068D0 (en) | Enzyme inhibitors | |
| GB201014190D0 (en) | Enzyme inhibition | |
| GB201014183D0 (en) | Enzyme inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |